Pheon’s lead program is a first-in-class antibody drug conjugate (ADC) against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.

The company is backed by healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.

In September 2022, the company laucnhed with $68 million in Series A financing.